Request Demo

Last update 29 Sep 2025

Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

Last update 29 Sep 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

Circumsporozoite protein hepatitis-B surface antigen fusion protein- GlaxoSmithKline, CSP-HBsAg - GlaxoSmithKlineCSP-HBsAg - GlaxoSmithKline, CSP-HBsAg/SBAS2-GlaxoSmithKline

+ [27]

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication

Malaria, Falciparum

Inactive Indication

Hepatitis BHIV InfectionsMeasles+ [2]

Originator Organization

GSK Plc

Active Organization

GSK Plc

Inactive Organization

University of Oxford

License Organization-

Drug Highest PhaseApproved

First Approval Date

Belgium (10 Jan 2015),

Malaria, Falciparum

Regulation-

Structure/Sequence

Sequence Code 126827

Clinical Trials associated with Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

NCT07036159

/ RecruitingPhase 2

A Phase 2a, Open Label, Randomized, Interventional Study to Assess the Safety and Immunogenicity of Alternative Vaccination Regimens and Reduced Antigen Doses of RTS,S/AS01E Vaccine in Healthy Children Aged 5-60 Months in a Malaria-endemic Area

The purpose of this study is to evaluate the safety and immunogenicity of reduced antigen doses and alternative vaccination regimes for RTS,S/AS01E in healthy children aged 5-60 months in a malaria-endemic area.

Start Date06 Aug 2025

Sponsor / Collaborator

GSK Plc

PACTR202409856142141

/ SuspendedNot ApplicableIIT

Evaluating antibody responses longitudinally and correlation to clinical malaria in children who received seasonal vaccination with RTS,S/AS01E with and without seasonal malaria chemoprevention in Mali.

Start Date01 Oct 2024

Sponsor / Collaborator-

NCT06424002

/ Not yet recruitingPhase 4IIT

The Impact, Feasibility Acceptability and Cost Effectiveness of the RTS,S/AS01 Malaria Vaccine in School Aged Children

Across sub-Saharan Africa, school-age children bear an under-appreciated burden of malaria. An estimated 200 million school-age children are at risk of malaria and in many areas prevalence of infection exceeds 50%. The high infection rates in this group serves as a source of onward parasite transmission, undermining elimination and control efforts. Furthermore, malaria illness and malaria-induced anemia in this age group lead to school absenteeism, and impaired cognitive function and classroom attention, ultimately resulting in reduced academic achievement. Although universal malaria interventions, such as insecticide treated nets (ITNs) and access to prompt diagnosis and treatment are available to school-age children, this age group is the least likely to benefit from these interventions. Furthermore, efficacy of these approaches may be compromised by increasing anti-malarial drug and insecticide resistance. A malaria vaccine could help to avert the burden of malaria in this age group.
The RTS,S/AS01 malaria vaccine has recently been recommended for vaccination of young children (< 24 months) by the World health organization (WHO) after a Phase 3 trial and an implementation trial showed that the vaccine had moderate but significant efficacy to prevent clinical and severe malaria in young children. Previous randomized trials suggest that the vaccine is safe for older children. However, efficacy of the vaccine has never been assessed in school age children. Kamuzu University of Health Sciences in partnership with the Malawian Ministry of Health seeks to evaluate the efficacy of the newly introduced RTSS/AS01 malaria vaccine in school aged children. The study hypothesizes that vaccination will decrease the morbidity and transmission of malaria, as well as improve school absenteeism and educational outcomes.

Start Date01 Jun 2024

Sponsor / Collaborator

Michigan State University

[+2]

100 Clinical Results associated with Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

100 Translational Medicine associated with Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

100 Patents (Medical) associated with Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

426

Literatures (Medical) associated with Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

01 Dec 2025·MOLECULAR BIOLOGY REPORTS

Mosquito-based transmission-blocking vaccine candidates for malaria: progress, challenges, and innovations

Review

Author: Yadav, Mahima ; Dahiya, Nisha ; Sehrawat, Neelam ; Kataria, Divya ; Janjoter, Sangeeta

Over the last two decades, a significant reduction has been seen in malaria-attributable morbidity and mortality but still, it remains a major public health burden in many countries. The outbreak of malaria due to climate change in some countries emphasizes the critical need for improved strategies to treat, prevent, and control malaria. Although WHO has recommended RTS, S/AS01, and R-21/Matrix-M (R21), these vaccines have shown lesser efficacy. The low efficacy of the vaccines emphasizes the need for discovering a promising vaccine. Present vaccines are parasite-based and can only reduce the severity of the disease and risk of death. Transmission-blocking vaccines (TBVs) can prevent the risk of the spread of infectious malaria disease worldwide. Several studies revealed that mosquito-based TBVs can effectively target a wide variety of parasites, and significantly reduce the survival rate of the vector. In the present review, various mosquito-based studies involving antisera-raising methods for evaluating transmission-blocking efficacy are included. This review focuses on the efforts made to justify a specific protein as a TBV candidate, the status of mosquito-based TBV antigens, challenges in developing potential mosquito-based TBV, and promising approaches for improving the transmission-blocking efficacy of the TBVs. This review gives an insight into the benefits of using mosquito-based TBVs as a transmission-blocking strategy for malaria.

01 Oct 2025·Lancet Global Health

Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial

Article

Author: Agbenyega, Tsiri ; Lee, Cynthia K ; Bii, Dennis K ; Otieno, Kephas ; Buabeng, Patrick Boakye Yiadom ; Samuels, Aaron M ; Adjei, Samuel ; Bakari, Ashura ; Osei-Tutu, Lawrence ; Fabre, Robin ; Ockenhouse, Christian F ; Ntiamoah, Yaw ; Oneko, Martina ; Ansong, Daniel ; Bollaerts, Anne ; Westercamp, Nelli ; Kotoh-Mortty, Maame Fremah ; Atieno, Cecilia ; Attobrah Sarfo, Maame Anima ; Kariuki, Simon K ; Schuerman, Lode ; Sang, Tony ; Ofori-Anyinam, Opokua

BACKGROUND:

We conducted a phase 2b trial evaluating fractional-dose and full-dose regimens of the RTS,S/AS01_E vaccine (RTS,S). All regimens provided substantial protection against clinical malaria in natural exposure settings, over 21 and 32 months of follow-up. Here, we present end-of-study results, after 50 months of follow-up.

METHODS:

This open-label, randomised controlled trial was conducted at two research centres in Agogo (Ghana) and Siaya County (Kenya) between Sept 28, 2017, and Nov 14, 2022. Children aged 5-17 months were randomly assigned (1:1:1:1:1) to one of five groups to receive rabies vaccine (the control group) at months 0, 1, and 2; or full doses of RTS,S at months 0, 1, and 2, followed by either full doses (R) at month 20 (group R012-20) or months 14, 26, and 38 (R012-14-26-38); or full doses at months 0 and 1, followed by fractional doses (Fx; one-fifth of full dose) at months 2, 14, 26, and 38 (Fx012-14-26-38) or months 7, 20, and 32 (Fx017-20-32). We present results of secondary objectives, evaluating vaccine efficacy, impact, immunogenicity, and harms up to month 50. Endpoints were the occurrence of clinical malaria meeting the primary and secondary case definitions and antibody responses at predefined timepoints, and the occurrence of solicited adverse events within 7 days from vaccination and serious adverse events and adverse events of special interest up to study end. This trial is registered at ClinicalTrials.gov (NCT03276962) and is complete.

FINDINGS:

Between Sept 28, 2017, and Sept 25, 2018, 2157 children were enrolled, of whom 1609 were randomly assigned (322 to each RTS,S group and 321 to the control group). Of these 1609 children, 1500 received at least one study vaccine dose (exposed set), and 1333 were included in the per-protocol set for efficacy. Among children in the exposed set, to month 50, vaccine efficacy against all episodes of clinical malaria was 36% (95% CI 19-50), 51% (37-61), 43% (28-55), and 41% (26-53) in groups R012-20, R012-14-26-38, Fx012-14-26-38, and Fx017-20-32, respectively (p<0·001 for all). The numbers of cases averted per 1000 RTS,S full-dose equivalents were 353 (R012-20 group), 544 (R012-14-26-38 group), 1151 (Fx012-14-26-38 group), and 1134 (Fx017-20-32 group). Vaccine efficacy and impact and immune responses were maintained over 50 months of follow-up in groups who received additional vaccine doses after the fourth dose. The vaccine was well tolerated; only five serious adverse events were considered to be related to vaccination. There were no deaths considered to be related to vaccination.

INTERPRETATION:

All RTS,S regimens provided substantial protection against clinical malaria, with additional yearly doses maintaining vaccine efficacy and impact up to 50 months. Using fractional-dose regimens could increase the availability of RTS,S and reduce vaccination cost.

FUNDING:

GSK; PATH (through the Bill & Melinda Gates Foundation and the German Federal Ministry of Education and Research).

15 Sep 2025·JOURNAL OF INFECTIOUS DISEASES

Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum-Exposed, Drug-Treated Kenyan Adults

Article

Author: Omondi, Mary ; Oyugi, Roselyne ; Gast, Chris ; Raine, Mike ; Lee, Cynthia K ; Onyango, Irene ; Otieno, Solomon ; Bergmann-Leitner, Elke S ; Chira, Salome ; Aponte, John J ; Otieno, Lucas ; Copeland, Nathanial K ; Akala, Hoseah ; Mercer, Laina D ; Andagalu, Ben ; Lievens, Marc ; Ivinson, Karen ; Ockenhouse, Christian F ; Amoit, Stellah ; Onditi, Amos ; Pindolia, Hema ; Wasuna, Ruth ; Gregory, Scott ; Otieno, June Doryne ; Locke, Emily ; Sifuna, Peter

Abstract:

Background:

RTS,S/AS01 vaccine efficacy (VE) was previously shown as lower in African adults than in malaria-naive US adults, potentially due to concurrent Plasmodium falciparum infections. We investigated whether treatment of infection prior to vaccination would lead to improved VE and immunogenicity.

Methods:

A phase 2b study in Kenyan adults evaluated the efficacy of RTS,S/AS01E in conjunction with antimalarial chemopreventive drugs. Participants, grouped by baseline presence or absence of P. falciparum infections, were randomized to receive RTS,S/AS01E or rabies vaccine. Four groups received antimalarial drugs prior to immunization and were followed for 6 months to assess P. falciparum infection. We included an additional group not treated with antimalarial drugs for immunological assessment.

Results:

VE (RTS,S/AS01E vs rabies vaccine) was 34.8% (95% confidence interval [CI], 8.9% to 53.4%) and −24.0% (95% CI, −97% to 22.4%) in baseline P. falciparum-positive and P. falciparum-negative participants, respectively. In RTS,S/AS01E recipients, there were no statistical differences in anticircumsporozoite (anti-CS) antibody titers in baseline P. falciparum-positive or P. falciparum-negative participants, or in susceptibility to infection during the postvaccination follow-up period. Drug treatment did not improve anti-CS antibody titers.

Conclusions:

Treating P. falciparum infections during vaccination does not result in increased VE. Anti-CS antibody responses to vaccination do not differ with baseline P. falciparum infection status, drug treatment, or susceptibility to P. falciparum infections.

Clinical Trials Registration:

NCT04661579; PACTR202006896481432.

News (Medical) associated with Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

25 Jun 2025

·www.fiercepharma.com

GSK, Bharat Biotech to slash the price of first malaria vaccine to less than $5 per dose by 2028

The gradual price cut to less than $5 per dose will take full effect in 2028, when GSK and Bharat Biotech fully complete their production transfer. As part of a multi-year collaboration, GSK and India’s Bharat Biotech are redoubling their efforts to bring the world’s first malaria vaccine to more countries in need at affordable prices.Mosquirix, or RTS.S., was brought to the world stage by GSK and PATH (formerly known as the Program for Appropriate Technology in Health) in 2021 as the first malaria vaccine recommended by the World Health Organization (WHO).Bharat Biotech, an established supplier to global vaccine alliance Gavi, quickly signed on to help with antigen manufacturing in a product transfer agreement meant to boost the long-term supply of the shot and deliver on GSK’s commitment to supply up to 15 million doses through 2028.Since then, Bharat Biotech has pumped more than $200 million into higher-output manufacturing facilities and other enhancements. Along with GSK’s own “significant investments” in production capacity and efficiency, the pair's production progress will now allow for a phased reduction in the price of the vaccine, the companies explained in a June 25 press release. The gradual price cut of more than 50% will commence immediately and reach a price of less than $5 per dose by 2028, according to the release."We partnered with Bharat Biotech in 2021 with a common goal: to find a sustainable solution to get ahead of malaria,” GSK’s Chief Global Health Officer Thomas Breuer said in the release. “Today, we announce GSK’s contribution to the long-term price ambition of the world's first malaria vaccine, a key milestone achieved through collaboration with Bharat Biotech and partners from Gavi, PATH and the WHO.”The commitment is part of a wider pledge to international vaccine alliance Gavi’s upcoming replenishment phase for 2026 through 2030.Dubbed Gavi 6.0, the alliance’s five-year strategic framework looks to scale up global access to vaccines, strengthen health systems and ensure sustainable immunization programs and vaccine markets through long-term, predictable funding. Gavi will have introduced Mosquirix to routine immunization programs in 12 endemic countries in Africa by the end of 2025, an achievement that has “only been possible through the critical work that GSK has undertaken with Bharat Biotech,” PATH, the WHO and other global health organizations, according to the GSK release.The latest agreement between GSK and Bharat Biotech puts Gavi’s goal of protecting at least 50 million more children across Africa from malaria by the end of 2030 “firmly in reach,” Gavi’s CEO Sania Nishtar, Ph.D., noted in the release. Nearly half of the world’s population is at risk of malaria, according to the WHO. Since 2000, investments in global malaria response have prevented more than 13 million deaths and at least 2 billion cases, but recent funding cuts to foreign aid could put malaria prevention programs in jeopardy. Most recently, the U.S.’s proposed 2026 budget includes a 47% cut to the U.S. President’s Malaria Initiative (PMI), which would slash annual funding to $424 million.“For the first time in decades, the number of kids dying around the world will likely go up this year instead of down because of massive cuts to foreign aid. That is a tragedy,” billionaire philanthropist Bill Gates warned in a statement. Gates' foundation, the Gates Foundation, on Tuesday chipped in $1.6 billion to support Gavi over the next five years ahead of a pledging event co-hosted by the foundation and the European Union that looks to raise at least $9 billion for Gavi. Meanwhile, GSK has been working on a next-generation malaria vaccine that would add a new antigen that works at a different life-cycle stage of the malaria parasite. In addition to greater disease protection, the second-generation program could reduce the number of booster doses needed, making it “more accessible and easier to implement in routine immunization programs,” GSK’s second-generation malaria vaccine program lead, Katie Ewer, said in a GSK post in April.

VaccineClinical Study

25 Jun 2025

·pharma.economictimes.indiatimes.com

Bharat Biotech Slashes Price of World's First Malaria Vaccine for Children in Africa to Under $5

Hyderabad: In a landmark move that promises to accelerate access to life-saving malaria prevention for children in Africa, Bharat Biotech and GSK today announced a significant price reduction for the world’s first malaria vaccine, RTS ,S. The vaccine will now be made available to endemic countries at less than $5 per dose by 2028—more than a 5o per cent price drop—thanks to manufacturing innovations, expanded production, and minimal profit margins. The announcement is part of the companies’ joint pledges to Gavi, the Vaccine Alliance, for its 2026–2030 replenishment strategy (Gavi 6.0), and comes as the RTS,S vaccine is on track to be rolled out in 12 African countries through routine immunisation programmes by the end of 2025, with Gavi’s support. RTS,S, developed by GSK in partnership with PATH and others, became the first malaria vaccine recommended by the World Health Organization (WHO) in 2021. Since then, GSK has been investing in scaling up production and transferring technology to Bharat Biotech. Simultaneously, Bharat Biotech has poured over $200 million into setting up high-output manufacturing infrastructure and product development. Dr. Krishna Ella, Executive Chairman of Bharat Biotech International Limited said: "This pledge to Gavi 6.0 is more than a pricing announcement. It's a commitment to global equity, innovation, and collaboration. Through this historic announcement, we aim to change the course of malaria burden for millions of children and families. By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria.” GSK’s Chief Global Health Officer, Thomas Breuer, echoed the sentiment: “Today marks a major milestone. Our work with Bharat Biotech has yielded crucial improvements in manufacturing efficiency and long-term affordability. This is how we change the trajectory of diseases like malaria.” Thomas Breuer, Chief Global Health Officer, GSK, said: “We partnered with Bharat Biotech in 2021 with a common goal: to find a sustainable solution to get ahead of malaria. Today, we announce GSK’s contribution to the long-term price ambition of the world’s first malaria vaccine, a key milestone achieved through collaboration with Bharat Biotech and partners from Gavi, PATH and the WHO. The GSK team has worked hand in hand with Bharat Biotech to transfer the vaccine manufacturing technology, while simultaneously implementing crucial improvements in manufacturing efficiencies, resulting in today’s pledge to the Gavi replenishment.” Malaria continues to kill over 600,000 people each year, primarily children under five in sub-Saharan Africa. Early results from WHO’s Malaria Vaccine Implementation Programme (MVIP) in Ghana, Kenya, and Malawi—where over 2 million children received the RTS,S vaccine between 2019 and 2023—show a 13% reduction in all-cause mortality and 22% fewer hospitalisations for severe malaria. “Vaccines like RTS,S are key tools in our malaria arsenal,” said Dr Sania Nishtar, CEO of Gavi. “This commitment by Bharat Biotech and GSK brings our goal of protecting 50 million more children by 2030 within reach.” Dr Kwaku Poku Asante, Director, Kintampo Health Research Centre in Ghana, highlighted the significance of the price cut: “A more affordable vaccine means more children in high-burden areas can be protected. Today’s announcement is a pivotal moment in global malaria control efforts.” As part of a broader malaria strategy, the vaccine complements existing tools such as seasonal chemoprevention, insecticide-treated nets, and indoor spraying. GSK also revealed that it is working on a next-generation vaccine targeting a different stage of the parasite’s lifecycle to further enhance protection and support eradication efforts. With price no longer a barrier, and with the strong backing of governments, researchers, and global health partners, today’s announcement sets the stage for one of the most ambitious malaria vaccination efforts ever undertaken in Africa. By Online Bureau ,

Vaccine

10 Jun 2025

·www.fiercepharma.com

Oxford taps CDMO Recipharm to handle additional manufacturing work in malaria vaccine collab

CDMO Recipharm and the University of Oxford have collaborated on malaria vaccines since 2016. Now, they have expanded their partnership as Recipharm will perform end-to-end manufacturing for two vaccines in early-stage trials. After combining on the development of five malaria vaccine candidates since 2016, Swedish CDMO Recipharm and the University of Oxford have expanded their collaboration to include additional manufacturing duties.For ongoing phase 1/2 trials, Recipharm will manufacture Oxford’s blood-stage malaria vaccine hopefuls R78C and RH5.1.Recipharm, which has already handled drug substance and drug product production for R78C, will now also take care of fill-finish services to meet the increased demand for vials for the ongoing trials.As for RH5.1, Recipharm will take over a role previously filled by another contract manufacturer, handling all aspects of production of the vaccine candidate, according to a June 9 press release.Blood-stage vaccines work by stimulating the immune system, decreasing the number of parasites in the blood and thereby reducing the severity of the disease.“Our ability to deliver drug substance and drug product for larger scales under GMP conditions makes us a strong partner for accelerating vaccine candidates from lab to clinic,” Greg Behar, CEO of Recipharm, said in a release.After seeing its revenue skyrocket by 30% in 2022 thanks to a partnership with Moderna to produce its COVID-19 vaccine, Recipharm has executed an ongoing transformation, mixing acquisitions and sell-offs. With the stagnancy of the CDMO industry, Recipharm has done more divesting of late, with the most notable move coming in 2024. Last year, the company inked a deal to sell seven manufacturing and development facilities—including five in its home country—to U.S. private equity firm Blue Wolf Capital.Meanwhile, Oxford has become one of the premier developers of malaria vaccines. In 2023, Oxford’s three-shot regimen R21/Matrix-M became just the second malaria vaccine endorsed by the World Health Organization (WHO) for children. It was authorized a year after GSK’s Mosquirix made the grade. Malaria vaccines have been challenging to develop. It took more than 30 years for GSK to get Mosquirix to the market.According to the WHO, there were 249 million cases of malaria around the world in 2022, with 608,000 deaths. In Africa, children under the age of 5 accounted for 76% of the malaria fatalities, the WHO said.

VaccineAcquisitionDrug ApprovalClinical Study

100 Deals associated with Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07X	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Malaria, Falciparum	Belgium	GSK Plc	10 Jan 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Measles	Phase 3	Ghana	GSK Plc	10 May 2017
Rubella	Phase 3	Ghana	GSK Plc	10 May 2017
Yellow Fever	Phase 3	Ghana	GSK Plc	10 May 2017
Hepatitis B	Phase 3	Burkina Faso	GSK Plc	17 Nov 2011
Hepatitis B	Phase 3	Ghana	GSK Plc	17 Nov 2011
HIV Infections	Phase 3	Kenya	GSK Plc	30 Jul 2010
Malaria	Phase 3	Burkina Faso	GSK Plc	27 Mar 2009
Malaria	Phase 3	Gabon	GSK Plc	27 Mar 2009
Malaria	Phase 3	Ghana	GSK Plc	27 Mar 2009
Malaria	Phase 3	Kenya	GSK Plc	27 Mar 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04661579 (PACTR202006896481432, Pubmed \| J Infect Dis)	Phase 2	Malaria, Falciparum Plasmodium falciparum	-	RTS,S/AS01E	iwfbbwtlkb(feckxegmcc) = luqhxlqmmo hvcogwsuof (clqexwpkbu, 8.9% - 53.4%)	Negative	29 May 2025
				Rabies vaccine	iwfbbwtlkb(feckxegmcc) = unudwiscmp hvcogwsuof (clqexwpkbu, -97% - 22.4%)
NCT04661579 (PACTR202006896481432, CTgov)	Phase 2	Malaria, Falciparum	620	Dihydroartemisinin-piperaquine (DHA/Pip)+Artemether / Lumefantrine+Primaquine+Malaria Vaccine RTS,S/AS01E (Group 1: Positive Parasitemia; Anti-malarial Treatment + RTS,S/AS01E Vaccine)	lwqbcywhcv = usdqifanoz taukjinevq (nlmplhsnwt, fnsprjturf - cytmyhokuj) View more	-	19 Jul 2024
				Abhayrab rabies vaccine+Dihydroartemisinin-piperaquine (DHA/Pip)+Artemether / Lumefantrine+Primaquine (Group 4: Positive Parasitemia; Anti-malarial Treatment + Rabies Vaccine)	lwqbcywhcv = vvvtttsrtz taukjinevq (nlmplhsnwt, gmdwmheaky - iiosifhndd) View more
NCT03276962 (phase 2b trial, CTgov)	Phase 2	Malaria	1,500	S+RTS,S/AS01E (Full dose) (Fx012-14-mFxD Group)	uihqitrynl = olneudzcni aknmvwwpgt (neuothvrba, ahjrrqoesn - mrbenrjgcb) View more	-	21 May 2024
				RTS,S/AS01E (Full dose) (R012-20 Group)	vqymklbifz = ckqyqmiocu djleefrrdx (rxgctwzmox, lmuanpwdnw - fajrfujeis) View more
NCT03162614 (Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults, Pubmed \| J Infect Dis)	Phase 2	Malaria Plasmodium falciparum-infected mosquito challenge	130	RTS,S/AS01B three-dose regimen	cfkaytbvey(vlnneeevfk) = vesdmamtdl muwojstnkt (njomgcfnyf, 27 - 72)	Positive	13 Oct 2020
				RTS,S/AS01E three-dose regimen	cfkaytbvey(vlnneeevfk) = zwpcdafpzg muwojstnkt (njomgcfnyf, 48 - 89)
NCT02699099 (CTgov)	Phase 3	Yellow Fever \| Malaria \| Rubella ... View more	699	Vitamin A+Stamaril+MR-Vac+Candidate Plasmodium falciparum malaria vaccine (Coad Group)	pzgwumhhqe(ixeyikasow) = qvfidbtshr eelpkxeyhv (cuflfrtafs, sehprabaxa - igavdsfzgu) View more	-	29 Aug 2019
				Vitamin A+Stamaril+MR-Vac+Candidate Plasmodium falciparum malaria vaccine (RTS,S Group)	pzgwumhhqe(ixeyikasow) = gretqalihc eelpkxeyhv (cuflfrtafs, wugjcffpsq - kmjasqtmuw) View more
NCT02207816 (CTgov)	Phase 3	Malaria	3,084	Blood sampling+Polio Sabin Oral Polio Vaccine+Malaria Vaccine 257049 (MALARIA-055 PRI) (GSK257049 Group)	deriwjoxte(tecgfnyeaf) = zmwlbccqgo btxbfxmxcv (skmlantpxm, ugqrrefgav - iuoyvpfxcy) View more	-	15 Aug 2019
				Blood sampling+Malaria Vaccine 257049 (MALARIA-055 PRI) (GSK257049 Comparator Group)	deriwjoxte(tecgfnyeaf) = zefhhwvzuz btxbfxmxcv (skmlantpxm, nyvabthfup - xddasnzekb) View more
NCT02992119 (RTSS, CTgov)	Phase 2	Malaria	193	S+AS01B+RTS (Group 1)	kajhglvkco = upwlwaurhj plkxitnbtj (qsunvlxnbs, divgfqttli - hvncwrdcgq) View more	-	29 Jul 2019
				Double RTS,S/AS01E Fractional dose (Group 2)	kajhglvkco = ufuxtpxqxu plkxitnbtj (qsunvlxnbs, dzizzzlaux - mltilmoyzc) View more
NCT03162614 (Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults, CTgov)	Phase 2	Malaria	154	Sporozoite-infected mosquitoes challenge.+RTS,S/AS01B (AduFx Group)	euwwgglwwn = zjphpochlf vhzagfmyxu (cvafmqjbak, nrybaxapxu - wrkrwtjzrm) View more	-	24 Jul 2019
				Sporozoite-infected mosquitoes challenge.+RTS,S/AS01E (2PedFx Group)	euwwgglwwn = orebbmnilg vhzagfmyxu (cvafmqjbak, jwlxagiqvs - luwwfxpcnt) View more
NCT01148459 (CTgov)	Phase 3	Malaria \| HIV Infections	200	GSK257049 vaccine (GSK257049 Group)	tnjnnjgmhe = ntkuqsqfmi dqnmftqdrr (xiobgopbhw, rvfvknjsat - dlipnfpuxj) View more	-	16 Jan 2019
				Verorab (Verorab Group)	tnjnnjgmhe = qorjhknoky dqnmftqdrr (xiobgopbhw, xxbrtsmgjk - cmsyxdredz) View more
NCT00380393 (RTS,S/AS01E, CTgov)	Phase 2	Malaria, Falciparum	894	GSK malaria vaccine 257049 Vaccine (GSK257049 Group)	jodkgvyklj = hcemnuhgiw krylfgcsvh (mwbgnkwqay, smcwwlnytc - oskzkcfunp) View more	-	03 Jul 2018
				Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine (Rabipur Group)	jodkgvyklj = yviatzwnvp krylfgcsvh (mwbgnkwqay, raoayxipjg - ubfcbxmmfk) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation